European CHMP recommends license extension of olaparib (Lynparza) for pancreatic cancer

The license extension is as monotherapy for the maintenance treatment of adults with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.


European Medicines Agency